279 related articles for article (PubMed ID: 36290887)
1. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma.
Boudin L; Morvan JB; Thariat J; Métivier D; Marcy PY; Delarbre D
Curr Oncol; 2022 Oct; 29(10):7718-7731. PubMed ID: 36290887
[TBL] [Abstract][Full Text] [Related]
2. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
[No Abstract] [Full Text] [Related]
3. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
Iyer PC; Dadu R; Gule-Monroe M; Busaidy NL; Ferrarotto R; Habra MA; Zafereo M; Williams MD; Gunn GB; Grosu H; Skinner HD; Sturgis EM; Gross N; Cabanillas ME
J Immunother Cancer; 2018 Jul; 6(1):68. PubMed ID: 29996921
[TBL] [Abstract][Full Text] [Related]
4. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report.
Luongo C; Porcelli T; Sessa F; De Stefano MA; Scavuzzo F; Damiano V; Klain M; Bellevicine C; Matano E; Troncone G; Schlumberger M; Salvatore D
Curr Oncol; 2021 Dec; 28(6):5401-5407. PubMed ID: 34940089
[TBL] [Abstract][Full Text] [Related]
5. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
7. Advances in targeted therapy for anaplastic thyroid carcinoma.
Qian C; Jiang L; Xu S; Wang J; Tan Z; Xin Y; Ge M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):685-693. PubMed ID: 35347921
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
Higashiyama T; Sugino K; Hara H; Ito KI; Nakashima N; Onoda N; Tori M; Katoh H; Kiyota N; Ota I; Suganuma N; Hibi Y; Nemoto T; Takahashi S; Yane K; Ioji T; Kojima S; Kaneda H; Sugitani I; Tahara M
Eur J Cancer; 2022 Sep; 173():210-218. PubMed ID: 35932627
[TBL] [Abstract][Full Text] [Related]
9. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C
Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127
[No Abstract] [Full Text] [Related]
10. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
11. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
[TBL] [Abstract][Full Text] [Related]
12. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
Hamamoto T; Kono T; Taruya T; Ishino T; Ueda T; Takeno S
Auris Nasus Larynx; 2022 Jun; 49(3):515-519. PubMed ID: 33109426
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
Kawamura Y; Saijo K; Imai H; Ishioka C
Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
16. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
18. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
19. Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.
Wang R; Yamada T; Arai S; Fukuda K; Taniguchi H; Tanimoto A; Nishiyama A; Takeuchi S; Yamashita K; Ohtsubo K; Matsui J; Onoda N; Hirata E; Taira S; Yano S
Mol Cancer Ther; 2019 May; 18(5):947-956. PubMed ID: 30926637
[TBL] [Abstract][Full Text] [Related]
20. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
Sparano C; Godbert Y; Attard M; Do Cao C; Zerdoud S; Roudaut N; Joly C; Berdelou A; Hadoux J; Lamartina L; Schlumberger M; Leboulleux S
Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
